

Title	Repigmentation of vitiligo with oral baricitinib
Running Title	Repigmentation vitiligo baricitinib
Keywords	Vitiligo; Baricitinib; Tofacitinib; Janus Kinase Inhibitors; Oral Administration
Authors	<p>Blake P. Mumford https://orcid.org/0000-0002-5141-3361 blake.mumford@indoctrinate.com.au Skin Health Institute, Carlton, Victoria</p> <p>Andrew Gibson Melbourne Rheumatology Group, Malvern, Victoria</p> <p>Alvin H. Chong Department of Dermatology St Vincent's Hospital Melbourne, Fitzroy, Victoria Skin Health Institute, Carlton, Victoria</p>
Conflict of interest	None
Acknowledgements	None
Funding	None

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1111/AJD.13348](https://doi.org/10.1111/AJD.13348)

This article is protected by copyright. All rights reserved

DR. BLAKE MUMFORD (Orcid ID : 0000-0002-5141-3361)

Article type : Case Letter

We report a case of vitiligo repigmenting after the patient was prescribed oral baricitinib, a new Janus kinase (JAK) inhibitor, for his concurrent rheumatoid arthritis.

A 67-year-old Caucasian male was referred with vitiligo affecting the hands and forearms which he first noticed in July 2018. His only significant medical comorbidity was rheumatoid arthritis, diagnosed in 2008 which predominantly affected the small joints of the hands and feet. Rheumatoid factor and anti-citrullinated protein antibodies were strongly positive. Anti-nuclear antibodies were present with a titre of 1:80, and anti-dsDNA antibodies were undetectable. Full blood count, renal function, and liver function tests were unremarkable. No histopathology was performed.

Previous treatments for his rheumatoid arthritis included methotrexate, prednisolone, leflunomide, tocilizumab, golimumab, and adalimumab. No previous topical or systemic treatment had been commenced specifically for vitiligo.

In August 2018, three weeks after developing vitiligo, oral tofacitinib 5mg BD was commenced as monotherapy for the treatment of his rheumatoid arthritis. Whilst taking tofacitinib he noticed no significant improvement in depigmentation. In January 2019, tofacitinib was substituted for baricitinib 4mg daily to reduce pill burden via daily dosing. At follow up eight months after the commencement of baricitinib, almost complete repigmentation of the hands and forearms was observed (Fig. 1 and 2). Treatment with both JAK inhibitors was well tolerated with no adverse effects.

Interferon gamma (IFN- γ) and the associated chemokine CXCL-10 are implicated in the pathogenesis of vitiligo and seem to maintain an active inflammatory process which destroys melanocytes¹. IFN- γ signalling is mediated by the Janus kinase-signal transducer and activator of transcription (JAK-STAT)

pathway, specifically via JAK1 and JAK2². JAK inhibitors can block this pathway and consequently the actions of IFN- γ and CXCL-10³.

Tofacitinib and ruxolitinib are first generation JAK inhibitors which inhibit JAK1/3 and JAK1/2 respectively⁴. Both of these agents can effect significant repigmentation in patients with vitiligo and response to treatment is usually observed rapidly⁵. However, concomitant stimulation of melanocytes via skin exposure to ultraviolet light appears to be required to achieve repigmentation².

To our knowledge this is the first published case of vitiligo responding to baricitinib. Baricitinib has recently been approved for the treatment of rheumatoid arthritis in Australia and differs from tofacitinib in that it preferentially inhibits JAK1/2 rather than JAK 3⁴. Given IFN- γ is mediated via JAK1/2, it has been suggested that JAK inhibitors which predominantly inhibit these JAKs may be more effective than others².

In this case treatment with tofacitinib for a period of six months did not result in repigmentation, suggesting that substitution with a different JAK inhibitor may be a viable strategy in refractory cases of vitiligo.

1. Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. *Sci Transl Med*. 2014;6(223). doi: 10.1126/scitranslmed.3007811
2. Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. *J Am Acad Dermatol*. 2017;77(4):675-682.e1. doi: 10.1016/j.jaad.2017.05.043
3. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nat Rev Rheumatol*. 2016;12(1):25–36. doi: 10.1038/nrrheum.2015.167
4. Relke N, Gooderham M. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature. *J Cutan Med Surg*. 2019; doi: 10.1177/1203475419833609
5. Craiglow BG, King BA. Tofacitinib citrate for the treatment of Vitiligo a pathogenesis-directed therapy. *JAMA Dermatology*. 2015;151(10):1110–2. doi: 10.1001/jamadermatol.2015.1520



ajd_13348_f1.png



ajd_13348_f2.png



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Mumford, BP; Gibson, A; Chong, AH

Title:

Repigmentation of vitiligo with oral baricitinib.

Date:

2020-11

Citation:

Mumford, B. P., Gibson, A. & Chong, A. H. (2020). Repigmentation of vitiligo with oral baricitinib.. *Australas J Dermatol*, 61 (4), pp.374-376. <https://doi.org/10.1111/ajd.13348>.

Persistent Link:

<http://hdl.handle.net/11343/275829>

File Description:

Accepted version